A 2020 Tel Aviv University trial found that 60 sessions of hyperbaric oxygen therapy lengthened telomeres by up to 20% and reduced senescent cells by up to 37% in adults over 64. Those numbers put HBOT in rare company among anti-aging interventions with measurable cellular biomarker changes.
Improving Cognitive Function and Neuroprotection
The brain uses approximately 20% of the body’s oxygen supply. Better oxygen delivery should help cognition, but the evidence from HBOT research goes beyond simple oxygen delivery. HBOT has been shown to improve cerebral blood flow in regions that decline with age, with associated cognitive improvements.
Research from the aging program at Shamir Medical Center found improvements in attention and information processing speed in elderly adults after 60 HBOT sessions, associated with increased cerebral blood flow. The 2024 physical enhancement RCT4 added controlled evidence that HBOT improves cardiac perfusion and aerobic capacity in older adults, which has downstream cognitive implications.
A 2021 review by Balasubramanian and colleagues9 examined HBOT’s role in cerebral microcirculation and age-related vascular cognitive impairment. They found HBOT increases brain oxygen partial pressure, reduces intracranial pressure, and may ameliorate microvascular pathologies associated with dementia and Alzheimer’s disease. This is preliminary mechanistic evidence, not clinical trial data.
Supporting Cardiovascular Health and Vascular Regeneration
The strongest controlled evidence for HBOT’s physical anti-aging effects comes from the cardiovascular data in the 2024 Hadanny RCT.4 Sixty-three adults over 64 were randomized to 60 HBOT sessions or control. The HBOT group showed:
- VO2Max/kg: +1.91 ml/kg/min, effect size 0.455 (p=0.003)
- VO2 at first ventilatory threshold: +160 ml/min (p<0.001), effect size 0.617
- Cardiac blood flow (MBF): effect size 0.797 (p=0.008)
- Cardiac blood volume (MBV): effect size 0.896 (p=0.009)
These are large effect sizes from a randomized controlled trial, making this the most compelling evidence in the aging program. The mechanism involves HBOT stimulating endothelial progenitor cells and angiogenesis, improving vascular function in a way that supports both physical performance and organ health.
Practical Considerations for Anti-Aging Protocols
Anti-aging HBOT protocols require commitment. The research used 60 sessions, 5 days per week, over 12 weeks at 2.0 ATA. Sessions run 90 minutes with intermittent air breaks. This is a meaningful time and financial investment.
Cost varies by location and facility. Clinical settings typically charge $150-$300 per session. A 60-session course runs $9,000-$18,000 at most facilities. HBOT is not FDA-approved for anti-aging, so insurance will not cover this application. Some patients use HSA or FSA accounts.
Soft chambers at 1.3-1.5 ATA have not been studied for anti-aging endpoints. The telomere, skin, and physical performance studies all used hard chambers at 2.0 ATA. For soft vs hard chamber comparisons, the anti-aging data specifically applies to hard chambers only.
Frequently Asked Questions
How long before you see anti-aging results from HBOT?
Most cellular changes in the research occurred over 60 sessions (3 months). Physical performance improvements were measurable after the full protocol. Telomere changes were assessed at 30 sessions, 60 sessions, and 1-2 weeks post-treatment in the Hachmo study.
Can HBOT actually reverse biological aging?
The 2020 telomere study showed reversal of specific aging biomarkers (telomere length, senescent cell populations) in a single uncontrolled trial. Whether this translates to reversal of biological age or clinical outcomes has not been demonstrated. The claim that HBOT “reverses aging” goes beyond what the current evidence supports.
What is the difference between mild and clinical chambers for anti-aging?
The anti-aging research exclusively used hard chambers at 2.0 ATA with 100% oxygen. Mild soft chambers at 1.3-1.5 ATA deliver substantially less oxygen and have no anti-aging research supporting them. If the mechanism requires the hyperoxic-hypoxic paradox at therapeutic intensities, lower-pressure soft chambers likely cannot replicate these effects.
Are there risks?
HBOT is generally safe under qualified medical supervision. Potential risks include ear or sinus barotrauma, oxygen toxicity at high doses, and temporary vision changes. People with untreated pneumothorax or taking certain chemotherapy drugs should not use HBOT. A 2022 cell study found that in cells with pre-existing mitochondrial dysfunction, hyperbaric oxygen may worsen mitochondrial function. Always consult a physician before starting.
Who Should Not Try HBOT
HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone.
Absolute Contraindications
- Untreated pneumothorax
- Certain chemotherapy drugs (bleomycin, cisplatin, doxorubicin, disulfiram)
Relative Contraindications
- Upper respiratory infection or sinus congestion
- Seizure disorder
- COPD
- High fever
- History of ear surgery or chronic ear problems
- Claustrophobia
- Pregnancy
References
- Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging. 2020;12(22):22445-22456. DOI: 10.18632/aging.202188. PMID: 33206062.
- Hachmo Y, Hadanny A, Mendelovic S, et al. The effect of hyperbaric oxygen therapy on the pathophysiology of skin aging: a prospective clinical trial. Aging. 2021;13(22):24500-24510. DOI: 10.18632/aging.203701. PMID: 34784294.
- Hadanny A, Forer R, Volodarsky D, et al. Hyperbaric oxygen therapy induces transcriptome changes in elderly. Aging. 2021;13(23):25090-25099. DOI: 10.18632/aging.203709. PMID: 34818212.
- Hadanny A, Sasson E, Copel L, et al. Physical enhancement of older adults using hyperbaric oxygen: a randomized controlled trial. BMC Geriatrics. 2024;24:537. DOI: 10.1186/s12877-024-05146-3. PMID: 38961397.
- Fu Q, Duan R, Sun Y, Li Q. Hyperbaric oxygen therapy for healthy aging: From mechanisms to therapeutics. Redox Biol. 2022;53:102352. DOI: 10.1016/j.redox.2022.102352. PMID: 35649312.
- Kamat S, Mendelsohn A, Larrick J. Rejuvenation Through Oxygen, More or Less. Rejuvenation Res. 2021;24(2):158-163. DOI: 10.1089/rej.2021.0014. PMID: 33784834.
- Fisher SM, Sherif RD, Borab ZM, et al. Hyperbaric Oxygen Therapy in Aesthetic Medicine and Anti-Aging: A Systematic Review. Aesthetic Plast Surg. 2024. DOI: 10.1007/s00266-024-04553-6. PMID: 39733047.
- Young HY, Lee S, et al. Hyperbaric Oxygen Increases Mitochondrial Biogenesis and Function. J Appl Physiol. 2025. DOI: 10.1152/japplphysiol.00428.2024. PMID: 40402925.
- Balasubramanian P, et al. Integrative Role of HBOT on Healthspan, Age-Related Vascular Cognitive Impairment, and Dementia. Front Aging. 2021;2:678543. DOI: 10.3389/fragi.2021.678543. PMID: 35821996.
- Godman C, Joshi RA, Giardina C, et al. Hyperbaric oxygen treatment induces antioxidant gene expression. Ann N Y Acad Sci. 2010;1197:178-183. DOI: 10.1111/j.1749-6632.2009.05393.x. PMID: 20536847.
You’ve heard about hyperbaric chamber anti-aging treatments lately. The science behind it is real, and growing. This therapy delivers 100% oxygen under increased pressure. Researchers have studied how this affects cellular aging for years. The results are hard to ignore, though they come with important caveats.
If you’re curious whether pressurized oxygen can slow aging at the cellular level, you’re in the right place. We’ll cover what the research actually shows, what’s still preliminary, and what a real protocol looks like.
The Science Behind Hyperbaric Oxygen and Cellular Aging
When you enter a hyperbaric chamber at 2.0 ATA, your lungs absorb substantially more oxygen than normal breathing allows. At clinical pressures, oxygen dissolves directly into blood plasma, cerebrospinal fluid, and lymph, not just red blood cells. This saturation triggers biological responses that influence how cells age.
The most well-known anti-aging research comes from the Sagol Center at Shamir Medical Center in Israel. Hachmo, Hadanny, and colleagues ran a series of studies on healthy adults over age 64 using a 60-session protocol at 2.0 ATA. The key findings included telomere lengthening of more than 20% across all immune cell types and a 37% decrease in senescent T helper cells.1 These are two hallmarks of aging being modulated by the same intervention.
An important caveat: the original telomere study had no sham control group and has not been independently replicated as of 2026. It should be understood as promising preliminary evidence, not established clinical fact.
Telomere Lengthening and DNA Protection
Telomeres are protective sequences at the ends of chromosomes that shorten with each cell division. When they shorten enough, cells enter senescence or die. Telomere length is a widely used biomarker of biological age.
In the 2020 prospective trial by Hachmo and colleagues,1 35 healthy adults over 64 underwent 60 HBOT sessions at 2.0 ATA. Telomere length increased by more than 20% in T helper cells, T cytotoxic cells, natural killer cells, and B cells. B cells showed the most dramatic change, with a 37.63% increase post-treatment (p=0.007). Senescent T helper cell populations decreased by 37.30% (p<0.0001) and senescent T cytotoxic cells by 10.96% (p=0.0004).
Before this study, no intervention had shown this magnitude of telomere lengthening in humans. Exercise, meditation, and dietary changes have shown modest slowing of attrition, but not active lengthening at 20%+. That said, the study lacked a control group, had high standard deviations (SD 23-53% for some measurements), and enrolled only 35 participants. Independent replication is needed before this can be considered established.
Mitochondrial Function and Energy Production Enhancement
Mitochondria convert nutrients into ATP. They become less efficient with age, contributing to fatigue, cognitive decline, and metabolic dysfunction. Repeated HBOT sessions have been shown to stimulate mitochondrial biogenesis through PGC-1alpha activation.
A 2025 cell study published in Journal of Applied Physiology8 confirmed that hyperbaric oxygen exposure increased mitochondrial biogenesis via the PGC-1alpha and Nrf2 pathways, enhanced antioxidant defenses, elevated mitochondrial oxygen consumption and ATP production. Importantly, the study also found that in cells with pre-existing mitochondrial dysfunction, hyperbaric oxygen may worsen function, not improve it. This is a clinically relevant caveat for patients with significant metabolic disease.
The mechanism is the hyperoxic-hypoxic paradox: high oxygen during the session, followed by return to normal pressure, creates a cycling signal that acts like a training stimulus for cells. Mild pro-oxidant stress triggers protective adaptations, similar to how exercise-induced muscle stress triggers strength adaptations.
Reducing Inflammation Through Senescent Cell Clearance
Chronic low-grade inflammation, sometimes called “inflammaging,” is a driver of age-related disease. Senescent cells are a major contributor. These cells have stopped dividing but remain metabolically active, secreting pro-inflammatory cytokines through the senescence-associated secretory phenotype (SASP).
The Hachmo 2020 trial found HBOT reduced senescent T helper cells by 37.30% (p<0.0001) and senescent T cytotoxic cells by 10.96% (p=0.0004).1 The proposed mechanism is that senescent cells, already under metabolic stress, are pushed past their threshold by the elevated oxygen demand during HBOT, triggering programmed cell death selectively in these compromised cells while healthy cells tolerate the same environment. This positions HBOT as a non-pharmacological approach to senolytic activity, though this mechanism has not been fully validated.
Enhancing Collagen Production and Skin Rejuvenation
A 2021 companion study from the same research group examined skin biopsies from 13 males (mean age 68.07) before and after 60 HBOT sessions.2 Results showed:
- Collagen density: significant increase (p<0.001, effect size 1.10)
- Elastic fiber length: significant increase (p<0.0001, effect size 2.71)
- Blood vessel formation: significant increase (p=0.02, effect size 1.00)
- Fiber fragmentation: significant decrease (p=0.012)
- Tissue senescent cells: significant decrease (p=0.03, effect size 0.84)
This was the first human study to show HBOT can modulate the pathophysiology of skin aging. The sample size (n=13) and absence of a control group limit conclusions, but the effect sizes are large and the findings are biologically plausible given what is known about HBOT and angiogenesis from wound healing research.
Improving Cognitive Function and Neuroprotection
The brain uses approximately 20% of the body’s oxygen supply. Better oxygen delivery should help cognition, but the evidence from HBOT research goes beyond simple oxygen delivery. HBOT has been shown to improve cerebral blood flow in regions that decline with age, with associated cognitive improvements.
Research from the aging program at Shamir Medical Center found improvements in attention and information processing speed in elderly adults after 60 HBOT sessions, associated with increased cerebral blood flow. The 2024 physical enhancement RCT4 added controlled evidence that HBOT improves cardiac perfusion and aerobic capacity in older adults, which has downstream cognitive implications.
A 2021 review by Balasubramanian and colleagues9 examined HBOT’s role in cerebral microcirculation and age-related vascular cognitive impairment. They found HBOT increases brain oxygen partial pressure, reduces intracranial pressure, and may ameliorate microvascular pathologies associated with dementia and Alzheimer’s disease. This is preliminary mechanistic evidence, not clinical trial data.
Supporting Cardiovascular Health and Vascular Regeneration
The strongest controlled evidence for HBOT’s physical anti-aging effects comes from the cardiovascular data in the 2024 Hadanny RCT.4 Sixty-three adults over 64 were randomized to 60 HBOT sessions or control. The HBOT group showed:
- VO2Max/kg: +1.91 ml/kg/min, effect size 0.455 (p=0.003)
- VO2 at first ventilatory threshold: +160 ml/min (p<0.001), effect size 0.617
- Cardiac blood flow (MBF): effect size 0.797 (p=0.008)
- Cardiac blood volume (MBV): effect size 0.896 (p=0.009)
These are large effect sizes from a randomized controlled trial, making this the most compelling evidence in the aging program. The mechanism involves HBOT stimulating endothelial progenitor cells and angiogenesis, improving vascular function in a way that supports both physical performance and organ health.
Practical Considerations for Anti-Aging Protocols
Anti-aging HBOT protocols require commitment. The research used 60 sessions, 5 days per week, over 12 weeks at 2.0 ATA. Sessions run 90 minutes with intermittent air breaks. This is a meaningful time and financial investment.
Cost varies by location and facility. Clinical settings typically charge $150-$300 per session. A 60-session course runs $9,000-$18,000 at most facilities. HBOT is not FDA-approved for anti-aging, so insurance will not cover this application. Some patients use HSA or FSA accounts.
Soft chambers at 1.3-1.5 ATA have not been studied for anti-aging endpoints. The telomere, skin, and physical performance studies all used hard chambers at 2.0 ATA. For soft vs hard chamber comparisons, the anti-aging data specifically applies to hard chambers only.
Frequently Asked Questions
How long before you see anti-aging results from HBOT?
Most cellular changes in the research occurred over 60 sessions (3 months). Physical performance improvements were measurable after the full protocol. Telomere changes were assessed at 30 sessions, 60 sessions, and 1-2 weeks post-treatment in the Hachmo study.
Can HBOT actually reverse biological aging?
The 2020 telomere study showed reversal of specific aging biomarkers (telomere length, senescent cell populations) in a single uncontrolled trial. Whether this translates to reversal of biological age or clinical outcomes has not been demonstrated. The claim that HBOT “reverses aging” goes beyond what the current evidence supports.
What is the difference between mild and clinical chambers for anti-aging?
The anti-aging research exclusively used hard chambers at 2.0 ATA with 100% oxygen. Mild soft chambers at 1.3-1.5 ATA deliver substantially less oxygen and have no anti-aging research supporting them. If the mechanism requires the hyperoxic-hypoxic paradox at therapeutic intensities, lower-pressure soft chambers likely cannot replicate these effects.
Are there risks?
HBOT is generally safe under qualified medical supervision. Potential risks include ear or sinus barotrauma, oxygen toxicity at high doses, and temporary vision changes. People with untreated pneumothorax or taking certain chemotherapy drugs should not use HBOT. A 2022 cell study found that in cells with pre-existing mitochondrial dysfunction, hyperbaric oxygen may worsen mitochondrial function. Always consult a physician before starting.
Who Should Not Try HBOT
HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone.
Absolute Contraindications
- Untreated pneumothorax
- Certain chemotherapy drugs (bleomycin, cisplatin, doxorubicin, disulfiram)
Relative Contraindications
- Upper respiratory infection or sinus congestion
- Seizure disorder
- COPD
- High fever
- History of ear surgery or chronic ear problems
- Claustrophobia
- Pregnancy
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
